Inside Bar (Bullish)
|Bid||38.13 x 3000|
|Ask||38.12 x 800|
|Day's Range||38.16 - 38.66|
|52 Week Range||36.17 - 54.93|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||7.49|
|Earnings Date||Jul 26, 2023 - Jul 31, 2023|
|Forward Dividend & Yield||1.64 (4.31%)|
|Ex-Dividend Date||May 11, 2023|
|1y Target Est||46.80|
Subscribe to Yahoo Finance Plus to view Fair Value for PFELearn more
Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors. Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation. David Jagielski (Bristol Myers Squibb): Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.
In the latest trading session, Pfizer (PFE) closed at $38.36, marking a +0.89% move from the previous day.
Shares of BioNTech (NASDAQ: BNTX) were up as by much as 5.3% on Friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its non-small cell lung cancer therapy candidate. The company focuses on immunotherapies to treat cancer, infectious diseases, and other diseases. BioNTech's shares have been sliding because sales of Comirnaty, the COVID-19 vaccine it developed with Pfizer, are falling.
Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.
FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.
Is Pfizer stock a buy after the company unveiled promising weight-loss results for its diabetes pill? Is PFE stock a buy or a sell right now?
Biohaven is coming "out of stealth mode," an analyst said Thursday as BHVN stock climbed for a fourth consecutive day.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.
Pfizer Inc said on Thursday data from late-stage trials showed its experimental combination of antibiotics was effective in treating deadly infections caused by drug-resistant bacteria. Deaths from antibiotic-resistant bacteria, also known as superbugs, have been on the rise globally, and health regulators have called for the development of newer treatments as resistance to older antibiotics grows. The late-stage studies compared the experimental combination of the antibiotics aztreonam-avibactam (ATM-AVI) and existing generic drug metronidazole with a combination of two older antibiotics - meropenem and colistin - to treat complicated intra-abdominal infections and types of hospital-acquired pneumonia.
In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […]
NEW YORK, June 01, 2023--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in treating serious bacterial infections due to Gram-negative bacteria, including metallo-β-lactamase (MBL)-producing multidrug-resistant pathogens for which there are limited or no treatme
Regardless of your investing experience or risk tolerance, putting cash into stocks takes a certain tolerance for volatility and uncertainty. Investing in wonderful businesses, diversifying the ones you own, holding onto those great companies through the market's highs and lows, and avoiding traps like market timing can help you outpace the returns of the average retail investor through the years. Pfizer (NYSE: PFE) caught the attention of many investors when it became one of the leading contenders in the race to get a COVID-19 vaccine to market.
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.
The shot won FDA approval as a new study finds a 14-percentage-point drop in vaccine confidence since the Covid pandemic.
The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc. Pfizer's vaccine was approved for people aged 60 and older, the company said, the same age group as GSK's shot. In a late-stage study, Pfizer's vaccine, to be sold under the brand name Abrysvo, was 67% effective among those aged 60 and older with two or more symptoms of RSV, and 85.7% against severe illness defined by three or more symptoms.
NEW YORK, May 31, 2023--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.
Shares of pharma titan Pfizer (NYSE: PFE) were up by 2.24% on moderate volume as of 2:29 p.m. ET Wednesday afternoon. Earlier Wednesday, The Wall Street Journal published a column questioning whether investors have turned too bearish on COVID-19 vaccine-makers like Pfizer. Pfizer's shares have fallen by as much as 30% this year in response to the anticipated drop in sales for its COVID-19 vaccine Comirnaty and antiviral treatment Paxlovid.
Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.
A highly lucrative weight-loss market could be the growth opportunity Pfizer needs to make the stock a better buy.
OVER $300 BILLION That's how much has been wiped off the combined market value of [Moderna](https://www.wsj.com/market-data/quotes/MRNA), [Pfizer](https://www.wsj.com/market-data/quotes/PFE) and [BioNTech](https://www.
Moderna Pfizer and its partner BioNTech are among the biggest losers in the healthcare sector this year, dropping more than 25% each. The declines have been driven by a sense that, as the Covid-19 emergency enters the rearview mirror, demand for boosters will continue to wane. Just last week, the European Commission cut the number of vaccines it is purchasing from Pfizer and BioNTech.
Which top-shelf dividend stocks are worth buying right now? Allstate (NYSE: ALL) and Pfizer (NYSE: PFE) are two near-locks to produce healthy levels of capital appreciation over the next five to 10 years. Allstate's 2023 Q1 earnings report isn't exactly a confidence-inspiring read.
Pfizer said Tuesday its experimental hemophilia treatment cut down on bleeding episodes in a pivotal study. But Pfizer stock dipped.